Small Offerings, Big Impact: Demystifying Micro-IPOs

Plus: AI news, Funding rounds, and IPOs.

Author

Carina Clingman
October 16, 2024

In partnership with

What is a micro-IPO, and why would a biotech consider one?

This week, we're examining micro-IPOs as a tool in your biotech funding toolbox.

I had the pleasure of speaking with David Sans, PhD, FAARM, MBA, who heads healthcare investment banking at EF Hutton. David brings a unique perspective to the table, having transitioned from a career in biotech to investment banking.

We explored the intricacies of micro-IPOs, a funding strategy that can be particularly beneficial for certain biotech companies. David shared insights on what makes a successful IPO, the importance of investor support, and his vision for the future of financial services in biotech.

Whether you're a biotech founder considering funding options or simply interested in the intersection of finance and biotech, this episode offers valuable insights. Check out the podcast for our full conversation.

What’s inside:

  • PODCAST EPISODE: Small Offerings, Big Impact: Demystifying Micro-IPOs in Biotech with David Sans, Head of Healthcare Investment Banking at EF Hutton

  • CAREER CORNER: Helping non-traditional workers transition into biotech (and how companies can get interns for free).

  • BIOTECH NEWS: Funding rounds this week, AI regulations and future plans in biotech and healthcare, and the MassBio Incubator

The Building Biotechs Podcast

Small Offerings, Big Impact: Demystifying Micro-IPOs in Biotech with David Sans, Head of Healthcare Investment Banking at EF Hutton - Building Biotechs

This week, I had an insightful conversation with David Sans, PhD, FAARM, MBA, who heads healthcare investment banking at EF Hutton. We discussed the intricacies of different Public Offering strategies, including micro IPOs, which offer a unique avenue for biotech companies. David provides a deep perspective on the strategic implications of IPOs for biotech funding. He emphasized the importance of investor support and strategic banking partnerships, especially for micro IPOs. We also discussed the potential of AI in reshaping financial services and the future of outcome-based pricing models in investment. David's personal insights reveal the demanding yet rewarding nature of investment banking and highlight crucial aspects to consider for those pursuing a career in this field.

Career Corner

Empowering Careers: Gloucester Biotechnology Academy's Pathway to Biotech - Biotech Career Coach

In this episode of the Biotech Career Coach Podcast, we revisit an interview with John Doyle, Education Director at the Gloucester Biotechnology Academy, originally conducted for the Building Biotechs podcast. We discuss pathways for individuals with little to no experience to enter the biotech industry, emphasizing the academy's role in re-skilling and transitioning careers through intensive training programs. John tells us about the academy's offerings, including a seven-month training curriculum followed by internships, industry partnerships, and their outreach through middle school programs to inspire young minds. We also highlight the Massachusetts Life Sciences Internship Challenge and the benefits it offers companies in hiring capable interns. The value of the program is showcased through alumni success stories and the academy's holistic support system for students.

Get a List of the Best HRIS/Payroll Software for Your Company

You can now use SSR's free HR software matching service to find the best HRIS, ATS, and Payroll Software for your company. SSR's HR software experts will tailor a vendor shortlist based on your unique needs, packaged with advice to save you time and money.

No fees, no commitments. Just insights from HR experts who truly understand these tools.

Join over 15,000 companies that SSR has helped find the right HR software!

Stories We’re Following

The Week’s 10 Biggest Funding Rounds: Form Energy Powers Up With $405M

What a week for big rounds — as nine of them hit $100 million or more. While there were no multibillion-dollar rounds like last week, there was still a lot of money invested into everything from renewable energy to biotech to a soccer entertainment company.

Vision 2030 Early-Stage Catalyst: Fueling Innovation in Massachusetts Biotech - MassBio

Imagine a small group of passionate scientists gathered in a cramped lab, where beakers bubble with the promise of groundbreaking treatments. This is how many biotech companies begin, driven by an idea that could change the world. However, the journey from concept to commercialization is fraught with challenges. At MassBio, we recognize that early-stage companies […]

How will regulators adapt to adaptive AI?

TORONTO—While the FDA has already doled out green lights to about 950 medical devices backed by artificial intelligence or machine learning, it has yet to approve a product that is capable of updating itself over time—one with the goal of becoming stronger as it meets more patients.

The White House, Microsoft, SaS, Foley Hoag & Astellas Offer AI Guidance to Investors. Part One: The Present

Before companies and investors look towards the future, they must first understand the opportunities and challenges AI presents to them. From the benefits included in advancing processes to cybersecurity hazards, AI innovation is a balanced scale of oppportunities and risks.

Opening Day: Another trio of biotech IPOs make Friday debut

The Partners Group-backed KinderCare sold 24 million shares for $24 each this Tuesday. At the IPO price, the childhood education company had a market value of $2.74B, based on the outstanding shares. Sky Quarry, Click Holdings, and SKK Holdings also opened for trading this week. Meanwhile, a new trio of biotech companies’ shares came to market on Friday as Upstream Bio, Ceribell and Camp4 Therapeutics each made their public debut. In mid-September, Bicara Therapeutics (BCAX), MBX Biosciences (MB

Did someone forward this to you? Wow, you have great friends! Join Our Newsletter to Stay Plugged In.